The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. Exploratory analyses were performed on the dataset (n = 497) of a phase III randomized placebo-controlled trial to examine the response to nilvadipine in AD subjects stratified by baseline AD severity into very mild (MMSE ≥ 25), mild (MMSE 20-24) and moderate AD (MMSE < 20). The outcome measures included total and subscale scores of the Alzheimer's Disease Assessment Scale Cognitive 12 (ADAS-Cog 12), the Clinical Dementia Rating Scale sum of boxes (CDR-sb) and the AD composite score (ADCOMS). Cerebrospinal fluid biomarkers Aβ38, Aβ40, Aβ42, neurofilament light chain (NFL), neurogranin, YKL-40, total tau and P181 tau (ptau) were measured in a subset of samples (n = 55). Regression analyses were adjusted for confounders to specifically examine the influence of nilvadipine and baseline AD severity on cognitive outcomes over 78-weeks. Compared to their respective placebo-controls, nilvadipine-treated, very mild AD subjects showed less decline, whereas moderate AD subjects showed a greater cognitive decline on the ADAS-Cog 12 test and the ADCOMS. A lower decline was observed after nilvadipine treatment for a composite memory trait in very mild AD subjects and a composite language trait in mild AD subjects. Cerebrospinal fluid Aβ42/Aβ40 ratios were increased in mild AD and decreased in moderate AD patients treated with nilvadipine, compared to their respective controls. Among moderate AD subjects, levels of ptau, total tau, neurogranin and YKL-40 increased in subjects treated with nilvadipine compared to placebo. These studies suggest that baseline AD severity influenced the treatment outcome in the NILVAD trial and that future clinical trials of nilvadipine should be restricted to mild and very mild AD patients. Trial Registration: NCT02017340 Registered 20 December 2013, https://clinicaltrials.gov/ct2/show/NCT02017340 EUDRACT Reference Number 2012-002764-27 Registered 04 February 2013, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27

[1]  Philip S. Insel,et al.  Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.

[2]  B. Lawlor,et al.  Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. , 2019, Hypertension.

[3]  M. Mullan,et al.  Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI , 2018, Front. Aging Neurosci..

[4]  R. Segurado,et al.  Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial , 2018, PLoS medicine.

[5]  L. Lannfelt,et al.  TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI-Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE , 2018, Alzheimer's & Dementia.

[6]  B. Lawlor,et al.  Exploratory analyses suggest less cognitive decline on nilvadipine treatment in very mild Alzheimer’s disease subjects , 2018, bioRxiv.

[7]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[8]  Suzanne E. Schindler,et al.  Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years , 2018, Alzheimer's & Dementia.

[9]  K. Blennow,et al.  24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial , 2017, The Lancet Neurology.

[10]  Linda J. C. van Waalwijk van Doorn,et al.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[11]  H. Struyfs,et al.  The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting , 2017, Journal of Alzheimer's disease : JAD.

[12]  E. Siemers,et al.  Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease , 2017, Alzheimer's & Dementia.

[13]  J. Morris,et al.  The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement , 2017, Alzheimer's & Dementia.

[14]  E. Siemers,et al.  Statistical properties of continuous composite scales and implications for drug development , 2017, Journal of biopharmaceutical statistics.

[15]  J. Morris,et al.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials , 2017, Alzheimer's & Dementia.

[16]  K. Blennow,et al.  Blood-based NfL , 2017, Neurology.

[17]  F. Lopera,et al.  Amyloid-beta immunotherapy: the hope for Alzheimer disease? , 2016, Colombia medica.

[18]  D. Bennett,et al.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. , 2016, Brain : a journal of neurology.

[19]  Philip S. Insel,et al.  Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease , 2016, EMBO molecular medicine.

[20]  K. Blennow,et al.  Alzheimer's disease , 2016, The Lancet.

[21]  R. Segurado,et al.  European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow , 2016, BMJ Open.

[22]  T. Montine,et al.  Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum , 2016, Journal of neuropathology and experimental neurology.

[23]  Jeffrey Cummings,et al.  ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  J. Sevigny,et al.  Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial , 2016, Alzheimer disease and associated disorders.

[25]  M. Markey,et al.  New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials , 2015, Alzheimer's Research & Therapy.

[26]  F. Crawford,et al.  The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation* , 2014, The Journal of Biological Chemistry.

[27]  R. Segurado,et al.  NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease , 2014, BMJ Open.

[28]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[29]  Christine Haberler,et al.  Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series , 2013, Acta Neuropathologica.

[30]  M. Carrillo,et al.  CSF biomarker variability in the Alzheimer's Association quality control program , 2013, Alzheimer's & Dementia.

[31]  B. Zlokovic,et al.  Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[32]  S. Hendrix,et al.  Introducing a new tool for optimizing responsiveness to decline in early Alzheimer's disease , 2012, Alzheimer's & Dementia.

[33]  D. Paris,et al.  Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. , 2011, European journal of pharmacology.

[34]  A. Owen,et al.  Working memory task performance and chunking in early Alzheimer's disease , 2011, British Journal of Psychiatry.

[35]  C. Volmar,et al.  Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier , 2011, Molecular medicine.

[36]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[37]  D. Knopman.  Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease , 2008, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[38]  H. Hanyu,et al.  Nilvadipine prevents cognitive decline of patients with mild cognitive impairment , 2007, International journal of geriatric psychiatry.

[39]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[40]  Fiona Crawford,et al.  Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice , 2004, Brain Research.

[41]  P. S. St George-Hyslop,et al.  Molecular genetics of Alzheimer's disease: the role of β-amyloid and the presenilins , 2000, Current opinion in neurology.

[42]  P. Davies.  Neurochemical studies: an update on Alzheimer's disease. , 1988, The Journal of clinical psychiatry.

[43]  K. Blennow,et al.  Alzheimer’s Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer’s Disease , 2019, The Journal of Prevention of Alzheimer's Disease.

[44]  Philip D. Harvey,et al.  Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. , 2017, Innovations in clinical neuroscience.

[45]  N. Cairns,et al.  Widespread tau seeding activity at early Braak stages , 2016, Acta Neuropathologica.

[46]  P. Passmore,et al.  The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? , 2012, Journal of Alzheimer's disease : JAD.

[47]  N. Moore.  Update on Alzheimer's disease. , 1997, Journal of the Medical Association of Georgia.

[48]  N. Venna,et al.  Reversible depression in Binswanger's disease. , 1988, The Journal of clinical psychiatry.

[49]  C. Paúl,et al.  Education, leisure activities and cognitive and functional ability of Alzheimer's disease patients: A follow-up study , 2013, Dementia & neuropsychologia.